1 April 2024 - The April 2024 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The April issue of the Schedule includes a few new/revised listings of note:

• Cemiplimab (Libtayo) - new indication
• Empagliflozin (Jardiance) - new indication
• Fluticasone propionate with salmeterol xinafoate (Salflumix Easyhaler) - new formulation
  
• Inclisiran sodium (Leqvio) - new medicine
• Methotrexate sodium (Trexject) - new indication
• Niraparib tosylate monohydrate (Zejula) - new indication
• Teriparatide (Terrosa) - new biosimilar medicine

Read Summary of PBS changes